Moro, Alejandro
Gao, Zhen
Wang, Lily
Yu, Aixin
Hsiung, Sunnie http://orcid.org/0000-0002-4813-7220
Ban, Yuguang http://orcid.org/0000-0002-2874-0647
Yan, Aimin
Sologon, Corneliu M.
Chen, X. Steven
Malek, Thomas R. http://orcid.org/0000-0001-7174-0434
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI148675)
Bristol-Myers Squibb
Article History
Received: 3 March 2021
Accepted: 10 March 2022
First Online: 21 April 2022
Competing interests
: The University of Miami and T.R.M. have patents pending on IL-2–CD25 fusion proteins (WO2016022671A1) and their use (PCT/US20/13152) that have been licensed exclusively to Bristol Myers Squibb, and this research has been supported in part by a collaboration and sponsored research and licensing agreement with Bristol Myers Squibb. The other authors declare no competing interests.